Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy

Overview

About this study

The purpose of this study is to identify hereditary causes of cardiomyopathy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Patients with a diagnosis of a non-MI SCA who survived
  • Patients with a non-MI SCD
  • Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected
  • Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)

Exclusion Criteria:

  • Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease
  • Significant coronary artery disease (Epicardial coronary artery stenosis >50%) which can explain degree of LV dysfunction
  • Those unwilling to provide written consent or assent

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Grace Lin, M.D.

Open for enrollment

Contact information:

Hannah Frost CCRP

(507)293-2762

Frost.Hannah@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20360191

Mayo Clinic Footer